Literature DB >> 12835230

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.

Obiageli N Onwuazor, Xiao-Yan Wen, Ding-Yan Wang, Lihua Zhuang, Esther Masih-Khan, Jaimie Claudio, Bart Barlogie, John D Shaughnessy, A Keith Stewart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12835230     DOI： 10.1182/blood-2003-04-1204

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

Review 1.  Validation and quality control of protein microarray-based analytical methods.

Authors:  Larry J Kricka; Stephen R Master
Journal:  Mol Biotechnol       Date:  2007-08-03       Impact factor: 2.695

2.  The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition.

Authors:  Juliya Kalinina; Kaushik Dutta; Dariush Ilghari; Andrew Beenken; Regina Goetz; Anna V Eliseenkova; David Cowburn; Moosa Mohammadi
Journal:  Structure       Date:  2012-01-11       Impact factor: 5.006

3.  Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms.

Authors:  A Zingone; C M Cultraro; D-M Shin; C M Bean; H C Morse; S Janz; W M Kuehl
Journal:  Leukemia       Date:  2010-04-15       Impact factor: 11.528

4.  Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.

Authors:  Vishwanathan Hucthagowder; Rekha Meyer; Chelsea Mullins; Rakesh Nagarajan; John F DiPersio; Ravi Vij; Michael H Tomasson; Shashikant Kulkarni
Journal:  Cancer Genet       Date:  2012-09

5.  Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.

Authors:  Nathalie Javidi-Sharifi; Elie Traer; Jacqueline Martinez; Anu Gupta; Takehiro Taguchi; Jennifer Dunlap; Michael C Heinrich; Christopher L Corless; Brian P Rubin; Brian J Druker; Jeffrey W Tyner
Journal:  Cancer Res       Date:  2014-11-28       Impact factor: 12.701

6.  Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Authors:  Jonathan J Keats; Christopher A Maxwell; Brian J Taylor; Michael J Hendzel; Marta Chesi; P Leif Bergsagel; Loree M Larratt; Michael J Mant; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

Review 7.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

Review 8.  Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.

Authors:  Johann Micallef; Moyez Dharsee; Jian Chen; Suzanne Ackloo; Ken Evans; Luqui Qiu; Hong Chang
Journal:  J Hematol Oncol       Date:  2010-04-07       Impact factor: 17.388

Review 9.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

10.  A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.

Authors:  Anna Mandinova; Vihren Kolev; Victor Neel; Bing Hu; Wesley Stonely; Jocelyn Lieb; Xunwei Wu; Claudia Colli; Rong Han; Michael J Pazin; Mike Pazin; Paola Ostano; Reinhard Dummer; Janice L Brissette; G Paolo Dotto
Journal:  J Clin Invest       Date:  2009-10       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.